At the news
? BULLISHIMPACT 5/10 PRESS-RELEASE filed Nov 9, 2026 at 08:30 ET
Celcuity announced FDA acceptance of its sNDA for REVTORPYK (gedatolisib) in HR+/HER2- advanced breast cancer with PIK3CA mutations, with a PDUFA date of June 25, 2027. This expands the potential label to all HR+/HER2- advanced breast cancer patients regardless of PIK3CA status, building on the July 2026 approval for PIK3CA wild-type tumors.
- FDA accepted sNDA for REVTORPYK in HR+/HER2- advanced breast cancer with PIK3CA mutation
- PDUFA goal date set for June 25, 2027
- Submission based on PIK3CA mutant cohort of Phase 3 VIKTORIA-1 trial
- REVTORPYK already approved (July 14, 2026) for PIK3CA wild-type advanced breast cancer
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access